期刊
ANNALS OF THE RHEUMATIC DISEASES
卷 73, 期 1, 页码 149-153出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2012-202424
关键词
Psoriatic Arthritis; Rheumatoid Arthritis; Epidemiology
类别
资金
- American College of Rheumatology
- Clinical and Translational Science Award at the University of Pennsylvania from the National Center for Research Resources [8UL1TR000003]
- NIH [T32 GM075766-05]
- American College of Rheumatology Research and Education Foundation
- Icelandic Research Fund [120433021]
- [R01AG025152]
- [R01HL111293]
- NATIONAL CANCER INSTITUTE [P30CA016520] Funding Source: NIH RePORTER
- NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000003] Funding Source: NIH RePORTER
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL111293, R01HL089744] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K24AR064310] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM075766] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON AGING [R01AG025152] Funding Source: NIH RePORTER
Background There are conflicting reports in the literature of the mortality risk among patients with psoriatic arthritis (PsA). The objective of this study was to examine the risk of mortality in patients with PsA compared with matched controls, patients with psoriasis and those with rheumatoid arthritis (RA). Methods A longitudinal cohort study was performed in a large UK medical record database, The Health Improvement Network, among patients with PsA, rheumatoid arthritis (RA) or psoriasis with data from 1994 to 2010. Unexposed controls were matched on practice and start date within the practice for each patient with PsA. Cox proportional hazards models were used to calculate the relative hazards for death. Results Patients with PsA (N=8706), RA (N=41752), psoriasis (N=138424) and unexposed controls (N=82258) were identified; 1442357 person-years were observed during which 21825 deaths occurred. Compared with population controls, patients with PsA did not have an increased risk of mortality after adjusting for age and sex (disease-modifying antirheumatic drug (DMARD) users: HR 0.94, 95% CI 0.80 to 1.10; DMARD non-users: HR 1.06, 95% CI 0.94 to 1.19) whereas patients with RA had increased mortality (DMARD users: HR 1.59, 95% CI 1.52 to 1.66; DMARD non-users: HR 1.54, 95% CI 1.47 to 1.60). Patients with psoriasis who had not been prescribed a DMARD had a small increased risk of mortality (HR 1.08, 95% CI 1.04 to 1.12) while those who had been prescribed a DMARD, indicating severe psoriasis, were at increased risk (HR 1.75, 95% CI 1.56 to 1.95). Conclusions Patients with RA and psoriasis have increased mortality compared with the general population but patients with PsA do not have a significantly increased risk of mortality.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据